Adenocin (Adenocin)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Similar drugsTo uncover
Dosage form: & nbsplyophilizate for the preparation of solution for intravenous and intramuscular administration
Composition:

Active Ingredients: nidide (nicotinamide adenine dinucleotide, NAD) 0.5 mg, beta-acetyl-digoxin 0.075 mg, oxyphedrine 0.3 mg, inosine 80 mg;

Excipients: sodium chloride.

Description:

Liofilizate white color, odorless.

Pharmacotherapeutic group:cardiotonic
ATX: & nbsp
  • Other cardiotonic drugs
    • Pharmacodynamics:

    Adenocin is a cardiotonic agent with a cardioprotective effect, the ability to suppress three key links of the systemic inflammatory response syndrome: endotoxemia, tissue hypoxia and dysfunction of the body's own defense systems. Adenocin stimulates the synthesis of adenosine triphosphate (ATP) in the cell itself by disinhibiting glycolysis, stimulating the activity of the tricarboxylic acid cycle and, as a consequence, transporting electrons to oxygen. As a result, Adenocin eliminates the energy-deficient state of the cell, not only in conditions of rest, but also under increased stress on the heart. It has a direct stimulating effect on the contractile and relaxation functions of the myocardium and restores the transport of calcium ions through the membranes of the cardiomyocyte.Adenocin significantly reduces the severity of stagnant phenomena in the large and small circle of blood circulation, reduces end-diastolic pressure, restores or significantly improves the parameters of central hemodynamics and heart geometry, reduces the degree of pulmonary hypertension and general peripheral vascular resistance. Reduces the need for myocardium in oxygen, overcomes the refractoriness of the myocardium to medication, even in severe forms of heart failure caused by non-coronary heart disease and cardiosclerosis. The drug has a vasodilating effect, improves microcirculation and collateral blood supply, enhances diuresis. Prevents and removes coronary spasm, reduces heart rate (heart rate) to normal and stabilizes blood pressure (BP) figures.

    Pharmacokinetics:

    With intravenous administration, the bioavailability of the main active ingredient (NAD) averages 85% (70-95%). The time to reach the maximum concentration is 10-18 minutes after the administration of 2 vials (ampoules) of Adenocin.The largest part of the dose is excreted in the first 4.5 hours after administration and is completely eliminated within 8 hours. The half-life period averages 3.8 hours. It penetrates the blood-brain barrier. If there is a violation of kidney function (a decrease in creatinine clearance of 30-60 ml / min) toxic concentrations in the body are not achieved. It is excreted mainly by the kidneys.

    Indications:

    Adenocin is indicated for use in the complex therapy of chronic heart failure due to non-coronary heart disease (myocarditis, dilated cardiomyopathy, cardiosclerosis), as well as postinfarction cardiosclerosis, chronic ischemic heart disease, chronic heart failure after heart surgery and in preparation for heart transplantation, combined and isolated mitral and aortic defects, ischemic cardiomyopathy, cardiopulmonary insufficiency, tachysystoles eskoy form of atrial fibrillation, paroxysmal supraventricular tachycardia, and ventricular; the drug can be used in cases where therapeutic doses of cardiac glycosides lead to the development of glycosidic intoxication.

    Contraindications:

    Hypersensitivity to the drug, individual intolerance, pregnancy and lactation, age to 18 years (efficacy and safety not established).

    Carefully:

    In severe renal failure, creatinine clearance less than 30 ml / min (clinical experience is limited), with simultaneous therapy with cardiac glycosides, cardiotonic drugs, antiarrhythmics.

    Dosing and Administration:

    Intravenous and intramuscular!

    Intravenously drip: the contents of 1-2 vials (ampoules) Adenocin diluted in 70-100 ml of 5% dextrose (glucose) or saline (with diabetes) and injected for 1 hour once or twice a day. The maximum daily dose of up to 4 vials (in ampoules) in 100 ml of 5% dextrose (glucose) twice a day, maintaining a dose when stabilizing the condition (reducing symptoms of CHF and improving central hemodynamics) 1-2 vials (ampoules) intramuscularly in 5 ml of water for injections.

    Intravenous bolus (very slow): the contents of 1-2 vials (ampoules) Adenocin diluted in 15-20 ml of 5% dextrose (glucose) or saline and injected for 15-20 minutes once or twice a day.The maximum daily dose of up to 4 vials (ampoules).

    Intramuscularly: enter the contents of 1-2 vials (ampoules) Adenozin dissolved in 5 ml of water for injection, 1-3 times a day. The maximum daily dose of 8 vials (ampoules).

    The course of treatment 10-40 days, depending on the severity of the disease, the severity of symptoms of chronic heart failure and the patient's response to ongoing therapy.

    Repeated courses are recommended to be conducted no less than 6 months after CHF III-IV functional class for NYHA - in 3 months.

    Side effects:

    Allergic reactions are possible.

    Overdose:

    There is no information.

    Interaction:

    Possible simultaneous therapy with nitrates (in various dosage forms), including prolonged action, as well as anticoagulants, diuretics, hypoglycemic agents for ingestion and insulin, blockers of "slow" calcium channels, including nimodipine, beta-adrenoblockers, angiotensin-converting enzyme inhibitors and other antihypertensive agents, lipid-lowering agents, non-steroidal anti-inflammatory drugs and antibacterial agents of various classes, gliatilin, potassium orotate, potassium chloride, prednisolone, analgesics, antihistamines, nootropics.

    Simultaneous use with cardiotonic means (dopamine, dobutamine), and tas well antiarrhythmics only for special indications.

    With simultaneous use with antihypertensive drugs, diuretics may increase their effect.

    Special instructions:

    With simultaneous use with cardiac glycosides and other cardiotonic drugs, antiarrhythmics and with malignant hypertension, it is necessary to monitor heart rate, blood pressure and ECG.

    Form release / dosage:Liofilizate for the preparation of solution for intravenous and intramuscular injection.
    Packaging:

    For 90.875 mg in the ampoule (vial).

    For 90,875 mg of the drug in glass bottles, sealed with stoppers and rolled with aluminum caps or sealed glass ampoules.

    For 5, 10 and 20 vials or ampoules with a knife or scarifier, if necessary for this type, placed in a pack of cardboard with instructions for use.

    Storage conditions:In a dry, protected from light and out of reach of children, at a temperature of 0 to 10 ° C.
    Shelf life:

    3 years.

    Do not use after the expiry date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LSR-008992/08
    Date of registration:18.11.2008
    The owner of the registration certificate:EGV-PHARMA, LLC EGV-PHARMA, LLC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp17.02.2016
    Illustrated instructions
      Instructions
      Up